News
ADYX
0.0001
-50.00%
-0.0001
NEXGEL to Present at the LD Micro Invitational XII on June 8, 2022
Langhorne, Pennsylvania--(Newsfile Corp. - June 1, 2022) - NEXGEL, Inc. (NASDAQ: NXGL) (NASDAQ: NXGLW) ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced...
Newsfile · 06/01 11:30
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera’s existing board members,...
GlobeNewswire · 05/16 12:00
NEXGEL to Report its First Quarter 2022 Financial and Operating Results on May 12, 2022
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that it will report its financial and operating results for the fi...
PR Newswire · 05/09 11:30
NEXGEL to Present at the Planet MicroCap Showcase 2022 in Las Vegas on Wednesday, May 4, 2022
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, CEO of NEXGEL, will participate at the Planet...
PR Newswire · 04/28 12:30
NEXGEL to Present at Maxim Group's 2022 Virtual Growth Conference
NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer of NEXGEL, will participat...
PR Newswire · 03/24 12:00
NEXGEL Reports Fourth Quarter and Full Year 2021 Financial Results
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full year periods...
PR Newswire · 03/21 20:00
NEXGEL to Report its Fourth Quarter and Full Year 2021 Financial and Operating Results on March 21, 2022
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that it will report its financial and operating results for the four...
PR Newswire · 03/17 12:30
NEXGEL Announces Launch of MEDAGEL Bug Bite Relief Patch
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the launch of its MEDAGEL Bug Bite Relief Patch. These coolin...
PR Newswire · 02/15 12:30
NEXGEL Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the launch of its MEDAGEL ClearComfort Hydrogel Patch. The pa...
PR Newswire · 01/12 12:30
NEXGEL Provides 2021 Year in Review
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetic, today is...
PR Newswire · 01/10 12:30
NEXGEL to Present at H.C. Wainwright's Bioconnect Conference
NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today a...
PR Newswire · 01/04 13:00
NexGel, Inc. Announces Closing of $14.2 Million Initial Public Offering
NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today a...
PR Newswire · 12/27/2021 18:16
Bucks County medical device developer goes public with $14.2M IPO
The company is the sixth local life sciences company to complete an initial public stock offering in 2021.
American City Business Journals · 12/23/2021 15:18
NexGel, Inc. Announces Listing on Nasdaq and Pricing of $14.2 Million Initial Public Offering
NexGel, Inc. ("NexGel" or the "Company") (Nasdaq:NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today an...
PR Newswire · 12/22/2021 01:05
More
Webull provides a variety of real-time ADYX stock news. You can receive the latest news about Adynxx through multiple platforms. This information may help you make smarter investment decisions.
About ADYX
Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.